<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10944594</article-id><article-id pub-id-type="pmc">2363520</article-id><article-id pub-id-type="pii">6691304</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1304</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Beretta</surname><given-names>G D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Michetti</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Belometti</surname><given-names>M O</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Gritti</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Quadri</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Poletti</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Labianca</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Medical Oncology Unit, <label>2</label>Pneumology Unit, <label>3</label>Radiotherapy Unit, Ospedali Riuniti, Largo Barozzi 1, Bergamo, 24100, Italy</aff><pub-date pub-type="epub"><day>16</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>5</issue><fpage>573</fpage><lpage>576</lpage><history><date date-type="received"><day>09</day><month>09</month><year>1999</year></date><date date-type="rev-recd"><day>02</day><month>03</month><year>2000</year></date><date date-type="accepted"><day>13</day><month>04</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Cisplatin-based combinations are efficacious in increasing the overall survival of patients with non-small cell lung cancer (NSCLC), but their toxicity makes them unsuitable for elderly and unfit patients. The primary objective of this non-randomized phase II study was to evaluate the feasibility and activity of the gemcitabine plus vinorelbine combination in previously untreated elderly and/or unfit patients with measurable stage III or IV NSCLC. Forty-three patients aged &#x02265; 65 years or with contraindications against cisplatin treatment (36 males and seven females: median age 66 years; range 48&#x02013;75: PS 0 = 11, PS 1 = 19, PS 2 = 13) received intravenous (i.v.) gemcitabine 1000 mg m<sup>&#x02013;2</sup>, followed by vinorelbine 25 mg m<sup>&#x02013;2</sup>i.v. on day 1 and 8 every 21 days. Fifteen patients (34.9&#x00025;) achieved partial remission (confidence interval: 27.6&#x02013;42.2&#x00025;) for a median duration of 6 months; the median survival of these patients has not yet been reached. A further 15 had stable disease for a median of 4 months and a median survival of 7 months. The 10 patients (23.2&#x00025;) who experienced disease progression had a median survival of 4 months. Three patients are not evaluable. The 1-year actuarial survival rate is 31.1&#x00025;. The treatment was well tolerated: only 35&#x00025; of the patients had grade 3 or 4 granulocytopenia on day 14, none experienced episodes of neutropenic fever, and there was no evidence of severe haematological toxicity upon recycling. Only 9&#x00025; of the patients suffered from gastrointestinal toxicity (grade 3); increased but reversible transaminase levels were observed in 11.6&#x00025;. In conclusion, the results of this phase II study show that the combination of gemcitabine and vinorelbine is active and well tolerated in NSCLC, and thus encourage its use in elderly or unfit patients. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>elderly patients</kwd><kwd>unfit patients</kwd><kwd>NSCLC</kwd><kwd>gemcitabine</kwd><kwd>vinorelbine</kwd></kwd-group></article-meta></front></article>


